

Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method

Ralf Gold, Michael Barnett, Andrew Chan, Huiyu Feng, Kazuo Fujihara, Gavin Giovannoni , Xavier Montalbán, Fu-Dong Shi, Mar Tintoré, Qun Xue, Chunsheng Yang and Hongyu Zhou

Ther Adv Neurol Disord

2023, Vol. 16: 1–24

DOI: 10.1177/
17562864231180734

© The Author(s), 2023.
Article reuse guidelines:
[sagepub.com/journals-
permissions](https://sagepub.com/journals-permissions)

Abstract

Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple sclerosis (MS). Its efficacy and safety profiles are supported by over a decade of experience. Differences exist between Asia and Europe/United States in the prevalence and characteristics of MS; most data for DMF are derived from populations outside Asia. DMF was recently (2021) approved for use in China. The objectives of this review were to evaluate the evidence for DMF's profile, to provide an update to healthcare providers on current knowledge surrounding its use and to assess the relevance of existing data to use in China. This study used a modified Delphi method based on the insights of a scientific Steering Committee (SC), with a structured literature review conducted to assess the data of DMF. The literature review covered all papers in English (from 01 January 2011 to 21 February 2022) that include 'dimethyl fumarate' and 'multiple sclerosis', and their MeSH terms, on PubMed, supplemented by EMBASE and CiteLine searches. Papers were categorized by topic and assessed for relevance and quality, before being used to formulate statements summarizing the literature on each subject. SC members voted on/revise statements, requiring $\geq 80\%$ agreement and $\leq 10\%$ disagreement for inclusion. Statements not reaching this level were discussed further until agreement was reached or until there was agreement to remove the statement. A total of 1030 papers were retrieved and used to formulate the statements and evidence summaries considered by the SC members. A total of 45 statements were agreed by the SC members. The findings support the positive efficacy and safety profile of DMF in treating patients with MS. Limited Chinese patient data are an ongoing consideration; however, based on current evidence, the statements are considered applicable to both the global and Chinese populations. DMF is a valuable addition to address unmet MS treatment needs in China.

Registration: Not applicable

Keywords: China, Delphi method, dimethyl fumarate, multiple sclerosis, review

Received: 20 December 2022; revised manuscript accepted: 20 May 2023.

Introduction

Differences in the incidence, prevalence, presentation and prognosis of multiple sclerosis (MS) have been observed between East Asian populations and the rest of the world.^{1–8} For example, the prevalence of MS is estimated as 2.39/100,000

in China, 8.62/100,000 in Southeast Asia, 142.81/100,000 in Europe and 43.95/100,000 globally.⁹

Dimethyl fumarate (DMF) is a fumaric acid ester used to treat MS.^{10–13} DMF (Tecfidera®;

Correspondence to:

Ralf Gold
Department of Neurology,
Ruhr University Bochum,
Bochum 44791, Germany.
ralf.gold@rub.de

Michael Barnett
Brain and Mind Centre,
University of Sydney
and Royal Prince Alfred
Hospital, Sydney, NSW,
Australia

Andrew Chan
Department of Neurology,
Inselspital (Bern University
Hospital), University of
Bern, Bern, Switzerland

Huiyu Feng
Department of Neurology,
The First Affiliated
Hospital of Sun Yat-sen
University, Guangzhou,
China

Kazuo Fujihara
Department of Multiple
Sclerosis Therapeutics,
Fukushima Medical
University School of
Medicine, Fukushima,
Japan

Gavin Giovannoni
Department of Neurology,
Blizard Institute, Barts
and the London School of
Medicine and Dentistry,
Queen Mary University of
London, London, United
Kingdom

Xavier Montalbán
Mar Tintoré
Neurology Department,
Multiple Sclerosis Center
of Catalonia (Cemcat),
Vall d'Hebron University
Hospital, Barcelona, Spain

Fu-Dong Shi
Department of
Neurology, Institute
of Neuroimmunology,
Tianjin Medical
University General
Hospital, Tianjin, China

Qun Xue
Department of
Neurology, First
Affiliated Hospital of
Soochow University,
Suzhou, China

Chunsheng Yang
Department of
Neurology, Tianjin
Medical University
General Hospital,
Tianjin, China

Hongyu Zhou
Department of
Neurology, West China
Hospital, Sichuan
University, Chengdu,
China

Biogen-Idec, Cambridge, MA, USA) was approved for treatment of MS in the United States in March 2013^{14,15} and the European Union (EU) in January 2014 (starting with 120 mg oral capsules, administered twice daily for 7 days, followed by a twice daily 240 mg maintenance dose).^{10,15} In Asia, DMF was approved in South Korea in July 2016 and in Japan in December 2016.^{16,17} DMF has been approved in other Asian locations including, but not limited to, India (February 2015), Hong Kong (March 2016), Singapore (July 2016) and Thailand (March 2020).^{18–21} DMF is a widely used oral disease-modifying therapy (DMT) for MS,²² having been prescribed to approximately 580,500 persons globally in the clinical trial and post-market settings, corresponding to 1,267,327 person-years of exposure through 30 June 2022 (data on file; published 2021 data),²³ and was approved for use in the People's Republic of China in 2021.³

Although there are more than 13 years of DMF data, including long-term follow-up from its pivotal clinical trials (DEFINE, CONFIRM) and the long-term extension study (ENDORSE),^{24–28} comparatively little of this data has been derived from East Asia.²⁵ It is therefore relevant to consider whether DMF performs similarly in treating these populations, as elsewhere in the world.

Early treatment of MS with DMT is part of the strategy to improve patient prognosis. It is important to continually assess what is known about different DMTs in the light of additional clinical trials and post-marketing studies and real-world experience, to evolve clinical practice. For example, MS organizations and working groups have demonstrated the value of updating practice through agreed statements on the use of DMTs during COVID-19.²⁹ With the recent approval of DMF in China, it is an opportune time to review global and Asian DMF practice. Therefore, the objective of this work was to use a modified Delphi method to assess the current use of DMF in clinical practice and identify considerations relevant for its use going forward, in China and other countries, so that these serve as a valuable resource to sharing up-to-date evaluation of evidence supporting good clinical practice for treatment of MS.

Methods

This study used a modified Delphi method (Figure 1) based on the insights of a scientific

Steering Committee (SC). First, a structured literature review was performed to identify relevant evidence addressing the question, 'How is DMF used in the treatment of MS?' The literature review considered results from a PubMed search (from 01 January 2011 to 21 February 2022) including the core search terms 'dimethyl fumarate' AND 'multiple sclerosis' and their MeSH terms (search strings are detailed in Supplemental material; literature search strategy in Figure 2). Additional terms were used to categorize results into relevant topics.

The main search was supplemented by additional searches of EMBASE and Citeline. The topics of interest were categorized as: efficacy, safety, mechanism of action, pharmacokinetics/pharmacodynamics (PK/PD), treatment sequencing, adverse event (AE) management, infection, progressive multifocal leukoencephalopathy (PML) risk, effects on haematological parameters, effects on organ systems, drug-drug interactions, pregnancy/lactation, COVID-19 and paediatric populations.

The literature was first screened by title and abstract by editorial support staff from MIMS Limited for relevance and quality. Due to the known level of variation in the formulation of compounded products,³⁰ only papers using commercially produced DMF were included. Quality was based on the totality of several factors: type of publication (guidelines > systematic reviews > meta-analyses > opinion pieces > case reports), study design (randomized controlled trials (RCTs) > observational or cohort studies > case studies; and direct comparisons were considered superior evidence to indirect comparisons) and study size (more than 500 participants > fewer than 500 participants). Funding sources were also noted. The culmination of these factors was reflected in an overall evidence rating (high, medium high, moderate, medium low and low). Statements were developed based on the evidence and reviewed by SC members along with the supporting evidence and evidence rating.

The SC comprised 14 expert members (neurologists) representing clinical expertise from Germany ($n=1$), United Kingdom ($n=1$), Australia ($n=1$), Spain ($n=2$), Japan ($n=1$), Switzerland ($n=1$) and China ($n=7$). SC members were selected based on their clinical experience with MS, publication record and any previous contributions to




Figure 1. Study flow for this modified Delphi process.

Each topic set underwent voting with thresholds for agreement of $\geq 80\%$ and disagreement of $\leq 10\%$. Statements not meeting the criteria were discussed at one of two online SC meetings for revision. For statements with a response exceeding the disagreement threshold, the second round had a voting option for statement deletion.

DMF, dimethyl fumarate; PACTRIMS, Pan-Asian Committee for Treatment and Research in Multiple Sclerosis; PML, progressive multifocal leukoencephalopathy.

MS treatment guidelines. For practicality, topics were split into two sets: Set 1 topics, for Statements 8–24, 29–33 and 40–41, were discussed at the first meeting and Set 2 topics, for Statements 1–7, 25–28, 34–39 and 42–46, were discussed at the second meeting (Figures 1 and 3). Each topic set underwent two or more anonymous voting rounds with thresholds for agreement of $\geq 80\%$ and disagreement of $\leq 10\%$. Statements not meeting the criteria were discussed at one of two online SC meetings for revision (Figure 1).

Voting administration, collation of responses, collating meeting minutes and statement revision were conducted by the editorial support team to

negate bias. In addition to ‘Agree’ and ‘Disagree’, SC members could indicate agreement ‘with revision’, with suggestions provided as free-text entries, which were collated for discussion with highlighting of the incorporated updates (examples given in Figure 1). Statements discussed during meetings were revised and re-circulated for a second round of voting. For statements with a response exceeding the disagreement threshold, the second round had a voting option for statement deletion. After two voting rounds for each statement set, statements requiring higher levels of agreement were revised and voted on in the same round until agreement was reached on either a revised wording or deletion of the statement.




Figure 2. Literature search strategy.

Where the level of disagreement was below the threshold, the statement was included, as such statements reflect majority opinion, although not necessarily unanimity. In situations where practice or evidence differed significantly between regions, statements about global and Chinese or East Asian populations are presented separately.

Results

A total of 965 papers were retrieved with the search terms and a further 70 distinct references (one duplicate was removed) were used to supplement the search from additional sources. The number of participants voting in each round and the levels of agreement attained are summarized in Figures 1 and 3, respectively.

In the first round of voting on Set 1 statements (expressed as per cent responses on total number of votes received on all statements), there was 81% agreement, 13% agreement with revisions, 3% requesting further discussion at the meeting and 3% disagreement. The level of overall agreement increased to 88% by the second vote, with a further 6% agreeing with revisions (4% disagreement and 2% suggested deletions).

For the Set 2 statements, at round 1 there was 70% overall agreement, 17% agreement with revision and 12% disagreement. After the second vote there was 94% overall agreement on the

statements, 5% agreement with revision and 1% disagreement.

The most common reason for disagreement in both sets was a perceived lack of supporting evidence. Agreement with revision was typically for the correction of language-related issues such as simplifying wording. In total, 45 statements were finally included (Figure 3).

Mechanism of action

Two statements were proposed on the mechanism of action of DMF. DMF's effects on the immune system are complex and multi-faceted (Figure 3, Statements 1 and 2); DMF influences both B cell and T cell populations and pro-inflammatory cytokine production to reduce inflammatory activity.^{31–37} One of the main pathways of activity of DMF is via nuclear factor erythroid 2-related factor 2 (Nrf2), which has anti-oxidative and anti-inflammatory effects.^{13,38–42} The anti-oxidative and anti-inflammatory effects of the Nrf2 pathway may contribute to the cytoprotective abilities of DMF.^{38,39} DMF may prevent demyelination and axonal loss through reduction in pro-inflammatory reactive astrocytes.⁴³ Changes in immune cell populations, including a reduction in pro-inflammatory Th17 cells and increase in Th2 naïve/anti-inflammatory cells, induced by DMF produce a net shift away from a pro-inflammatory immune state.⁴⁴ Reductions

Category	Agreed statement	Evidence rating	Vote 1 responses	Vote 2 responses	Vote 3 responses
Mechanism 	1) DMF is thought to exert its clinical effects in multiple sclerosis via anti-inflammatory and anti-oxidative pathways. The precise mechanism of action of DMF continues to be investigated	+/Medium high			N/A
	2) DMF has potential multifaceted and beneficial effects on central nervous system cells, including modulation of microglia via the NR12 pathway	+/Medium high			N/A
PK/PPD and dose adjustments 	3) DMF is rapidly metabolized to monomethyl fumarate (MMF), which is CNS and CSF penetrant, and does not accumulate due to a short half life	=/Moderate		N/A, agreed at meeting	N/A
	4) Taking DMF with a meal changes the PK/PPD of DMF by delaying T _{max} and reducing C _{max} , without changing AUC; these changes do not affect the clinical effectiveness parameters of DMF	+/Medium high			N/A
Efficacy 	5) Taking DMF with a meal may lower the likelihood of a patient experiencing flushing or severe gastrointestinal adverse events, potentially by delaying T _{max} and reducing C _{max}	+=/Moderate high			N/A
	6) No DMF dose adjustments are needed for body weight, age, Asian ethnicity, sex or mild to moderate renal or hepatic impairment	+/Medium high			N/A
Hematology & infection risk 	7) DMF is an efficacious therapy for relapsing-remitting MS; it reduces relapses, annualized relapse rates, radiological evidence of disease, serum neurofilament light levels, and disability progression	+/High		N/A	N/A
	8) Early, compared with later, initiation of disease-modifying therapy offers greater long-term clinical benefit for patients	+/High			N/A
Hematology & infection risk 	9) In treatment-naïve patients, serum neurofilament light chain levels (sNFL) may predict response to disease modifying therapies including DMF; DMF reduces levels of sNFL in such patients after initiation	+=/Moderate high		N/A	N/A
	10) DMF treatment is associated with a decline in absolute lymphocyte counts over the first year of treatment, which then typically stabilises; the degree of lymphopenia is not conclusively linked with efficacy	+/High		N/A	N/A
	11) The risk of infections in patients with lymphopenia receiving DMF is low in most cases; nonetheless, ongoing monitoring of absolute lymphocyte count remains important	+/High			N/A
	12a) Prolonged severe/grade 3 lymphopenia, with absolute lymphocyte counts <500 mm ³ (0.5 x 10 ⁹ /L), is rare but a reason for discontinuation, that healthcare providers should be aware of and check for	+/High			N/A
	12b) Prolonged severe/grade 3 lymphopenia, with absolute lymphocyte counts <500 mm ³ (0.5 x 10 ⁹ /L), is rare but a risk factor for progressive multifocal leukoencephalopathy	+/High			N/A
	13) Factors influencing the risk of progressive multifocal leukoencephalopathy (PML) with DMF include age (≥50 years) and prolonged severe (≥grade 3) lymphopenia; PML may occur without severe prolonged lymphopenia	+/High			N/A
	14) Existing strategies for the detection of PML should be implemented where clinically relevant; and management of PML should include consideration of cessation of immunotherapy	EO			N/A
	15) Severe opportunistic fungal, bacterial, and viral infections are very rare with DMF, but patients should still be monitored for such infections	+/Medium high			N/A
	16) Currently, there is no evidence suggesting that treatment with DMF leads to immunoglobulin deficiency	=/Moderate			N/A
	17) Latent tuberculosis infection (LTBI) may be more common in China than in patients included in the clinical trials of DMF. However, the risk of reactivation of LTBI in patients treated with DMF appears to be low	=/Moderate			N/A



Figure 3. (Continued)





Category	Agreed statement	Evidence rating	Vote 1 responses	Vote 2 responses	Vote 3 responses
Comorbidities, organ function and cancer risk 	18) Cardiovascular disease can be comorbid with MS and lifestyle modification should be undertaken; DMF has not been associated with cardiovascular adverse events	+/Moderate high	92 8	100	N/A
	19) In patients with liver disease, DMF or another disease modifying therapy (DMT) with low hepatic toxicity may be a preferred treatment option	=/Moderate low	62 15 15 8	100	N/A
	20) DMF transiently elevates ALT/AST (grade 1) in some patients, but the elevation is seldom persistent or severe (≥grade 3) or causes discontinuation	+/High	100	N/A	N/A
	21) Universal screening for HBV and HCV is needed before initiation of most DMTs for MS; as-needed/periodic or 6-monthly liver monitoring is sufficient to assess risk of liver toxicity while on DMF	+/Medium high	77 15 8	91	9
	22) DMF has a very low risk of liver injury based on post-marketing data	+/Moderate high	62 31 8	82	18
	23) DMF is not associated with higher risk of malignancies or neoplasms, but clinicians should be vigilant for such risk	+/Medium high	100	N/A	N/A
Treatment initiation & decision-making 	24) DMF is suitable as a first-line therapy for patients with relapsing/remitting multiple sclerosis or clinically isolated syndrome, due to its good balance of efficacy and safety	+/Medium high	33 50 17	100	N/A
	25) In patients initiating treatment with DMF, the starting dose is normally maintained for 7 days; however, gradual up-titration to the full dose may be recommended for up to 4 weeks to minimize adverse events	+/Medium high	92 8	92	8
	26) Shared-decision making is important in multiple sclerosis care, goal setting and treatment strategy should be undertaken collaboratively and calibrated by patient desires; sensitivity to adverse events and family planning are especially important	=/Moderate	83 17	92	8
	27) Best disease control, as evidenced by a proxy like NEDA-3 (no relapses, no new radiological evidence of disease, no disability progression) or above is the current benchmark treatment goal in multiple sclerosis therapy	+/Medium high	83 8 6	83	17
	28) DMF is an effective and well-tolerated therapy in both treatment-naïve patients and those switching from other first-line therapies	+/Moderate high	77 23	100	N/A
Treatment sequencing 	29) DMF discontinuation is most commonly due to adverse events occurring early after initiation; particular attention should be paid to early tolerability of DMF to ensure patient safety and enable persistence	+/High	92 8	100	N/A
	30) Patients should switch DMTs as early as possible if an adequate trial of their current DMT shows a lack of efficacy or an intolerable adverse event profile; clinical judgement should be used regarding the duration for assessing adequacy of DMT treatment, which will differ based on the DMT	+/Medium high	85 15	82	18
	31) Treatment inertia may delay switching, and latency to initiation of an effective therapy may result in poorer outcomes	+/Medium high	92 8	N/A	N/A
	32) In patients who develop lymphopenia on DMF, consider avoiding switching to other DMTs that may also deplete lymphocytes	+/Medium high	62 8 23 8	91	9
Adverse event management 	33) Patients benefit from counselling and education on the adverse event profile of DMF, especially in the early phase of treatment; these activities set expectations, improve tolerance of adverse events, and promote persistence and adherence	+/High	92 8	N/A	N/A
	34) Gastrointestinal adverse events may be prevented or mitigated by taking doses with food, gradually up-titrating to the full dose, symptomatic therapies, or temporary dose reduction	+/High	100	100	N/A
	35) Flushing may be prevented or mitigated by taking doses with food or the use of symptomatic therapies such as aspirin or antihistamines	+/Medium high	92 8	N/A	N/A
	36) In patients treated with DMF, hypersensitivity reactions are uncommon, typically present as skin lesions (urticaria), and are responsive to steroids and antihistamines	0/Medium low	75 17 8	92	8



Figure 3. (Continued)

Category	Agreed statement	Evidence rating	Vote 1 responses	Vote 2 responses	Vote 3 responses
DMF and symptomatic treatments	37) DMF has no known drug-drug interactions, and symptomatic non-pharmacological and pharmacological therapies, including corticosteroids, may be used as required in treated patients	+/Medium high	58 33 8	100	N/A
	38) DMF may be safely used alongside aspirin, antihistamines, proton pump inhibitors and similar therapies for symptomatic relief of adverse events and to improve tolerability	+/Medium high	92 8	100	N/A
COVID-19 vaccine strategies	39) The risks of MS relapse and associated disability outweigh the hypothetical risk of more severe COVID-19 due to DMT-related immunosuppression; DMF should not be discontinued due to the risk of contracting COVID-19 alone	+/Medium high	92 8	91 9	N/A
	40) Having MS does not increase the risk of adverse events with vaccines studied to date; DMF does not impair the humoral immune response to COVID-19 vaccination and should be maintained, irrespective of the timing of vaccination	+/Medium high	77 15 8	100	N/A
Pregnancy/Lactation	41) There is no clear evidence of teratogenicity with DMF from clinical trials or post-marketing data	+/=Moderate high	50 25 25	92 8	N/A
	42) In patients who may become pregnant, DMF use can be considered until a pregnancy is confirmed	=0/Moderate low	33 8 58	83 8 8	N/A
Pediatrics	43) There is insufficient data regarding the use of DMF during breastfeeding. The metabolites of DMF are present in small quantities in the breast milk of lactating patients, the benefit of treatment should be weighed against the potential risk to the breast fed infant	00/Low	42 17 42	92 8	N/A
	44) Due to the lack of drug-drug interactions with DMF, hormonal contraception can be used as normal in patients taking DMF	=/Moderate	75 8 17	100	N/A
45) Limited data from open-label studies in pediatric populations aged ≥ 13 years suggest that DMF has similar efficacy and safety to adult populations at the same dose		=/Moderate	Statement: source = the meeting		N/A



Figure 3. Summary of voting responses and guiding statements on clinical use of dimethyl fumarate in treating multiple sclerosis.

Each topic set underwent anonymous voting rounds with thresholds for agreement of $\geq 80\%$ and disagreement of $\leq 10\%$. Statements not meeting the criteria were discussed at one of two online SC meetings for revision (Figure 1). For statements with a response exceeding the disagreement threshold, the second round had a voting option for statement deletion. ALT, alanine transaminase; AST, aspartate aminotransferase; AUC, area under the curve; C_{max} , maximum concentration; CNS, central nervous system; COVID-19, coronavirus disease of 2019; CSF, cerebrospinal fluid; DMF, dimethyl fumarate; DMTs, disease-modifying therapies; EO, expert opinion; HBV, hepatitis B virus; HCV, hepatitis C virus; LTBI, latent tuberculosis infection; MMF, monomethyl fumarate; MS, multiple sclerosis; N/A, not applicable; NEDA-3, no relapses, no new radiological evidence of disease activity, no disability progression; Nrf2, nuclear factor erythroid 2-related factor 2; PK/PD, pharmacokinetic/pharmacodynamic; PML, progressive multifocal leukoencephalopathy; SC, Steering Committee; sNFL, serum neurofilament light chain; T_{max} , time to maximum concentration.

in memory T and B cells similarly reduce over-active immune responses and the resulting neuronal damage in MS.^{36,44}

PK/PD and dosing

Upon ingestion, DMF is rapidly metabolized to monomethyl fumarate (MMF), which can cross the blood-brain barrier to exert its effects (Figure 3, Statements 3–6).^{39,40,45} MMF does not accumulate in the body, owing to a short terminal half-life of ~1 h.⁴⁵ A high-calorie and fat-rich meal delays T_{max} by hours and reduces C_{max} by approximately 40%.⁴⁵ However, area under the curve is not affected by taking DMF with a meal, which enables DMF to maintain efficacy, while reducing side effects.^{10,45} The impacts of having a meal on T_{max} and C_{max} reduce both gastrointestinal (GI) AEs and flushing, thereby alleviating DMF's most common undesired effects.^{46,47} Patients with severe renal or hepatic dysfunction were excluded from the pivotal clinical trials of DMF. However, neither condition is expected to influence the level of exposure to MMF.^{10,12}

Situation in China/East Asia. The studies in East Asian patients used the same dose regimen and reported a consistent AE profile for DMF, as the pivotal trials, which largely included Caucasian patients.^{16,48–50} No change in dosing is required for this population.

Efficacy statements

Three efficacy statements were included (Figure 3, Statements 7–9). The overall level of evidence for the efficacy of DMF was considered high, albeit with varying ratings for individual parameters. For relapse rate/annualized relapse rates (ARRs), radiological evidence of disease activity and disability progression, the data are derived from several large RCTs, meta-analyses and systematic reviews,^{25–28,49,51–53} and have been incorporated into guidelines from all major MS organizations, including in Japan.^{16,54–56} The pivotal clinical trials most convincingly demonstrated improvements in relapse rate/ARR with DMF treatment.^{25–28} Long-term data support that DMF treatment results in reductions in disability progression, with few overall relapses, but members of the SC considered this to have less strong support than the stated effects on ARR.⁵⁷ Radiological evidence of disease activity is perhaps the least well-supported parameter

of this set, given more variability in magnetic resonance imaging (MRI) assessment across centres and studies and therefore a lower quality of evidence.⁵¹ Despite the varying level of evidence for different aspects of efficacy, the overall position of the SC is that data exist for improvements on each of these parameters.

The importance of initiating a DMT soon after diagnosis is highlighted in several international guidelines^{54,55} and is supported by convincing evidence from both individual trials (including DMF specifically) and reviews.^{58–60} The SC noted the strong evidence for this statement and encourages early, appropriate initiation of a DMT.

Serum neurofilament light chains (sNFLs) are a marker of neuroinflammation and are thought to represent a proxy measure for axonal damage in MS.⁶¹ sNFL is reduced by DMTs in MS,⁶² and lower baseline sNFL levels in a small ($n=80$) observational trial predicted a greater response to DMF treatment, assessed by achieving no evidence of disease activity (NEDA) and reducing effector immune cells.⁶¹ The study concurs with a slightly larger trial ($n=127$) which showed that DMF reduced NFL in the blood and cerebrospinal fluid (CSF) of treatment-naïve patients and could normalize the CSF levels in 73% of participants.⁶³ As a comparatively new outcome measure with limited use in clinical practice, sNFL relevance for prognosis or disease outcomes requires further research. Nonetheless, DMF has shown some effects on this marker, and it may be a potential proxy measure for treatment response or prognosis.

Situation in China/East Asia. Evidence for efficacy of DMF in the East Asian population comes primarily from Japan, which contributed the majority (80%) of the East Asian population ($n=142$) in the APEX study, followed by South Korea (14%).^{48,49} A post hoc sub-analysis of Asian data from Fox *et al.*² has also been performed, confirming treatment efficacy and positive benefit-risk balance. In general, treatment results are similar between East Asian and Caucasian/rest-of-the-world populations, although there is lower incidence of MS but potentially poorer prognosis in Asian populations, possibly due to increased frequency of spinal lesions in this population and incomplete resolution of first attacks. There is no predicted difference for Asian populations which would lead to preferring later

treatment initiation, and considering a higher potential first-year relapse rate and poorer prognosis,^{2,64} it may be high priority to initiate treatment of Asian patients early in the clinical course. Many patients with MS in China do not initiate a DMT at the earliest opportunity⁴ for reasons of cost,³ perception of the condition as ‘mild’ and the advice of neurologists and other healthcare professionals.^{3,4} The treatment pattern in China continues to evolve, with early diagnosis and sustained use of DMTs during periods of remission becoming more common.³

Haematologic parameters and infection risk

Seven statements on haematological parameters and infection risk achieved agreement (Figure 3, Statements 10–17). In general, the risk of lymphopenia with DMF was recognized – but also that this did not translate to a substantial increase in risk of infections. Very rare occurrences of PML warrant clinical vigilance.

Lymphopenia. DMF studies consistently show a ~30% decline in mean absolute lymphocyte count in treated patients, which typically stabilizes within 6–12 months of treatment initiation.^{48,65–67} Lymphopenia is a risk factor for (serious) opportunistic infections and associated mortality in the general population.^{68,69} For this reason, it is important to monitor lymphocyte counts in patients receiving a therapy which may induce lymphopenia, such as DMF.^{70,71} However, the degree of lymphopenia induced by DMF has not been associated with increased incidence of serious infections,^{44,65,72} despite some case reports and database review findings of opportunistic infections.^{69,73–80} Degree of lymphopenia has also been proposed by some to predict better responses to DMF, as a proxy measure for a less overactive immune response and pro-tolerogenic profile,^{44,70,71,81,82} but most of the data have come from relatively small studies. The data are equivocal, as some studies (e.g. Longbrake *et al.*³¹) including larger controlled trials have found no relationship between lymphopenia and therapeutic efficacy of DMF.^{31,44,65} It has also been determined that CD4⁺ and CD8⁺ T cell counts correlate with absolute lymphocyte counts, suggesting that separate monitoring is not required.⁶⁷ After treatment discontinuation, most patients with lymphopenia experience recovery of lymphocyte count; the extent and duration of lymphopenia influence the time required to attain

this.⁸³ In the opinion of the SC, the data are insufficient to conclusively link lymphopenia with therapeutic efficacy, and lymphopenia is not recommended for use as a prognostic factor.

Vaccination response. Potential suppression of the immune system by DMTs is a risk factor not only for infections but also for a blunted response to vaccination, resulting from a reduced humoral and/or cellular response.^{29,84,85} The PROCLAIM study assessed immunoglobulin levels in patients initiating DMF and found no impact of DMF on immunoglobulin levels.⁴⁴ Similarly, immune response to vaccination was found to be similar between DMF and interferons.^{86,87} The SC therefore supports the conclusion that DMF does not interfere with vaccination.

Tuberculosis. Active tuberculosis infections need to be excluded before starting DMF treatment. In the EU/European Economic Area (EEA), tuberculosis has been estimated to occur at approximately 9.6 cases per 100,000 population (2019).⁸⁸ In comparison, the rates in China are estimated to be as high as 58 per 100,000 population, with substantially higher rates of latent infection (2019).⁸⁹ In general, screening for latent tuberculosis may be considered before initiating DMF,^{90–92} however, DMF is not one of the DMTs for which screening is mandatory.^{90–93} The risk for reactivation of latent tuberculosis infection appears to be low,^{91,93,94} and the decisions regarding testing ultimately lie with the treating physician.

Progressive multifocal leukoencephalopathy. Several DMTs have been associated with PML, caused by reactivation and viral replication of John Cunningham Virus (JCV) in glial cells, which then causes demyelination.^{23,95,96} PML is very rare and, in the cases that exist, occurs more commonly in immunocompromised patients.⁹⁵ As of 1 September 2022, there have been 12 cases of PML reported in approximately 580,500 patients treated with DMF, a rate of ~1/50,000 patients (0.9/100,000 patient years of DMF exposure)^{23,95} (data shown: on file; previous data referenced).²³

Prolonged Grade 3 lymphopenia is a risk factor for PML and a reason to discontinue DMF therapy.^{29,97} Based on reported trial data, it is estimated that around 5–10% of patients treated with DMF will experience Grade 3 lymphopenia, and 2.2% of patients will have prolonged

(≥ 6 months) Grade 3 lymphopenia.^{65,98} However, only a few cases have been reported of patients experiencing complications from prolonged severe lymphopenia.^{65,97,99,100} Age ≥ 50 years is another risk factor for PML; however, neither age ≥ 50 years nor severe prolonged lymphopenia are absolute identifiers of those at increased risk of PML, with recorded case reports in patients without these characteristics.^{95,101–103}

Closer monitoring of patients with a higher risk of PML is recommended. This includes monitoring for lymphopenia^{23,29} and regular (every 6–12 months) MRI scans.^{16,103} Discontinuing the suspected causative agent is recommended when patients develop PML.¹⁰⁴

Situation in China/East Asia. The high incidence of latent tuberculosis infection in China^{89,105} and infrastructural challenges in the availability of testing pose a practical obstacle to implementing routine screening before initiating DMF. However, as the risk of reactivation is considered very low,^{91,93,94} the recommendation for China is that screening for *latent* infections is *not* mandated.

Through the risk stratification process for PML with natalizumab, clinicians in China may be aware of the use of the JCV antibody index. Based on high JCV antibody positivity detected in MS patients from Hong Kong, JCV seropositivity is expected to be high in China.¹⁰⁶ However, JCV seropositivity does not play a role in risk stratification for DMF. For clinical practice in China, it is important to note that JCV index testing is *not* required with DMF; age and lymphopenia are sufficient criteria for determining PML monitoring.^{16,29,95} Clinical vigilance for this condition remains very important, despite its rarity.

Comorbidities, organ function and cancer risk

Four statements on comorbidities and organ function were approved, mostly with a focus on cardiovascular and hepatic safety (Figure 3, Statements 18–22). As MS causes progressive disability, patients are encouraged to maintain a healthy lifestyle, including a balanced diet combined with an exercise programme at a tolerable level.¹⁰⁷ Patients with MS are at higher risk of several forms of cardiovascular disease, including myocardial infarction and heart failure.¹⁰⁸ DMF is not associated with cardiovascular AEs such as

arrhythmia or hypertension and is unlikely to contribute to cardiovascular morbidity in patients with MS.^{109,110}

Drug-induced liver injury is a recognized risk for patients receiving DMTs for MS.¹¹¹ Alanine transaminase (ALT)/aspartate aminotransferase (AST) elevations have been reported in major trials of most DMTs, including DMF.^{25,26,48,50,112,113} With DMF, persistent or severe ALT/AST derangement or discontinuation due to liver toxicity occurred in < 1 –2% of clinical trial participants.^{28,112} Post-marketing evidence has identified ALT/AST elevation as relatively common; however, outright liver injury/hepatotoxicity has been recorded in very few DMF-treated patients ($n = 4$ –14).^{109,112} In light of the low risk of liver toxicity with DMF, periodic laboratory testing (up to regular 6-monthly testing) is sufficient to monitor for liver toxicity.^{29,112} To date, the number of reported cases of hepatotoxicity with DMF is limited to 14, plus one case of acute hepatitis E virus infection.^{112,114,115} Of those 14 cases, the earliest elevations of ALT/AST were recorded shortly after treatment initiation; liver injury was mild (six patients) or moderate/severe (eight patients) and there were no cases of liver failure.¹¹⁵

In patients with liver disease, DMF may be used with caution, at its normal dosage, as it is metabolized independently of the cytochrome P450 system.¹¹² Any risk of exacerbation or reactivation of hepatitis B virus (HBV)/hepatitis C virus (HCV) infection is mitigated in part by screening for these infections before initiation of most DMTs.¹¹²

Situation in China/East Asia. HBV and HCV are more common in China than in the EU,¹¹⁶ meaning that the requirement to screen for these viruses may yield positive results more frequently. With positive results, antiviral therapy and adjustments to the initiation of DMT should be considered; specialist assistance from hepatology or infectious disease colleagues is required to determine the appropriate course of action.¹¹²

Cancer risk. A single statement was proposed for cancer risk (Figure 3, Statement 23). An increased risk of malignancy in patients with MS has been investigated repeatedly, including in those with long-term use of DMTs.¹¹⁷ Overall, the malignancy rate in patients treated with DMF is similar

to age- and sex-matched individuals without MS.¹¹⁸ Duration of DMF treatment was concluded as a risk protective factor against neoplasms, in a small Spanish study.¹¹⁹ Recent database analyses have produced conflicting results, with one finding no evidence of an increased cancer risk¹²⁰ and the other being the first publication to find an increased risk of neoplasm with DMF.¹²¹ Consequently, it may be prudent to be vigilant in checking for cancer in DMF-treated patients, but this does not yet support a malignancy rate higher than the general population.¹¹⁸

Treatment initiation and decision-making

Location and licencing determine the permitted indications for DMF. If permitted by the local label, DMF can be used in both patients with relapsing-remitting multiple sclerosis (RRMS) and patients with clinically isolated syndrome (CIS).¹² The efficacy and tolerability of DMF are well balanced, and it is suitable as an initial therapy.^{27,28,122–132} The SC proposed four statements on this topic (Figure 3, Statements 24–27).

Early-in-treatment challenges with tolerability are the largest reason for the discontinuation of DMF.^{133,134} To mitigate the risk of AEs, a more gradual up-titration to the target dose may be considered for up to 4 weeks.^{10,135–137} It is important to note that the full dose is required for efficacy. Positive relationships between healthcare providers and patients are an important part of goal setting, partly through enhancing adherence. Self-management by patients may be improved by participation in a shared decision-making process.¹³⁸ Treatment selection will partly depend on the goals of the patient.^{138–141} These aspects of positive patient relationships may help to enhance tolerability when starting a new therapy. As treatments for MS have advanced, the achievable treatment goals/targets have evolved. NEDA-3 (no relapses, no new radiological evidence of disease activity, no disability progression) is the current benchmark proxy for best disease control.^{142–145} It may be beneficial to explain this as a target to patients as part of the goal-setting process.

Treatment switching

Five treatment switching statements were approved (Figure 3, Statements 28–32). Evidence for the profile of DMF was initially established in

comparison with both placebo and glatiramer acetate in the DEFINE, CONFIRM and ENDORSE trials.^{25–28,113} ENDORSE re-randomized patients previously treated with glatiramer acetate to DMF, with similar efficacy and tolerability results to those reported in treatment-naïve patients.²⁸ Outside pivotal clinical trials, these findings are further supported by observational studies of patients switching from other first-line therapies to DMF.^{122,124,132,146–151} Based on these results, horizontal switching, especially from injectable therapies, is a viable use of DMF.

Early (*versus* later) initiation of an effective DMT is linked to better long-term outcomes for patients with MS (see efficacy statements, Figure 3, Statements 7–9), exemplified by achieving NEDA-3 with DMF.^{49,54,55,58,151} Treatment inertia may delay switching, and latency to initiation of an effective therapy may result in poorer outcomes, meaning that in addition to initiating DMTs early, switches should be considered if a therapy has proved intolerable or has shown a lack of efficacy in the judgement of the treatment team.^{29,142}

When switching to a new therapy it is important to consider its characteristics, to properly prepare the patient for the switch.⁵⁶ The most common AEs of DMF treatment are GI symptoms and flushing.^{26,46,152} Discontinuation of DMF is more commonly attributable to tolerability issues (68% of discontinuing patients cited this as the main reason for discontinuation) than to a lack of efficacy (15% of patients).^{134,153} However, a study of 886 patients in Spain reported similar rates of DMF discontinuation as a consequence of AEs and lack of efficacy (13.2% and 13.5% of patients, respectively).^{133,150} Side effects resulting in discontinuation most commonly occur early in treatment,^{153,154} suggesting that particular attention can be paid to mitigating AEs and promoting tolerability in the early period of treatment. Rarely, discontinuation may be due to lymphopenia. As a general principle, if a therapy is discontinued for a particular AE, switching to a therapy with a similar AE profile may not be the most appropriate choice. With DMF, limited evidence from a small observational study has suggested that lymphocyte counts may not recover in patients who discontinued therapy and switched to other lymphodepleting agents, because of lymphopenia.¹⁵⁵ Out of caution, such switches should be avoided if possible. A United States study reports that most patients who

discontinued DMF with lymphopenia experienced lymphocyte count reconstitution.⁸³

Situation in China/East Asia. In China, as many as 58% of patients do not initiate DMTs upon their diagnosis of MS.³ The reasons include cost, a historical lack of available DMTs and low patient acceptance of therapy for what they may erroneously perceive as a ‘mild’ condition.⁴ Many patients will therefore be initiating DMF treatment while DMT-naïve. There are no contraindications to initiating therapy with DMF based on prior steroid or other therapies,^{10,12} but the timing of initiation may depend on satisfactory condition of the patient, as judged by the neurologist, for example without lymphopenia from corticosteroid or azathioprine use.

Adverse event management and tolerability

As with treatment initiation, important considerations for AE management and tolerability are counselling, shared decision-making and mitigation strategies (Figure 3, Statements 33–36). Forward planning, counselling and expectation setting all assist adherence with DMF by improving tolerability.^{46,136,137,156,157} Involving patients in goal setting and integrating their preferences into therapy management is beneficial for initiating DMTs in MS.^{136,156}

Mitigation of AEs primarily involves either GI symptoms or flushing.⁴⁶ Symptomatic therapies for GI AEs include proton pump inhibitors, antihistamines and assorted other agents for nausea such as metoclopramide, domperidone, diphenhydramine and dimenhydrinate.^{46,135} Gradual up-titration (over 4 weeks) or temporary reductions in dose when an AE is encountered help to mitigate the risk of discontinuation.^{136,137} The goal is still to achieve the full dose, consistently, as it is required for efficacy.⁴⁶ Taking DMF with food continues to be recommended to mitigate GI AEs.^{136,157,158}

For flushing, aspirin (75–325 mg) daily, or every second day, can be used typically as pre-treatment 30 min before DMF.^{11,46,136,159,160} Antihistamines are only rarely required but can also be used.^{136,137} Metoprolol, acetaminophen, ibuprofen, cosmetics and counselling have been used for flushing by at least one respondent in a consensus statement.⁴⁶

There have been few reports of hypersensitivity in the literature, despite large numbers of patients treated with DMF.^{161–165} Where they have occurred, management has shown a response to steroid and antihistamine treatment.

Concomitant therapies

Two statements summarize DMF use with symptomatic treatment (Figure 3, Statements 37 and 38). Corticosteroids are commonly used in the treatment of acute relapses in patients with MS.^{16,54,145} While DMTs aim to avoid relapses, if they occur it is important that the DMT does not prevent acute or symptomatic therapy from being undertaken. DMF has no known drug-drug interactions,^{10–12,166} including with single doses of interferon beta-1a (IFN-β1a) and glatiramer acetate, or aspirin. The former characteristic facilitates switching, whereas the latter facilitates symptomatic mitigation of flushing symptoms.⁴⁶ GI adverse effects and flushing are the most common side effects with DMF.⁴⁶ Symptomatic therapies such as antihistamines (flushing), proton pump inhibitors (GI) and aspirin (flushing), among others, can be used to mitigate these AEs and improve tolerability.^{46,137,152} Aspirin mitigates flushing without increasing GI AEs.¹⁵⁹

In total, the lack of drug-drug interactions means that AEs and relapses may both be managed without concern for the patient’s DMF use.

COVID-19 and vaccinations

The use of DMTs during the COVID-19 pandemic has been an important and vibrant topic of clinical consideration. The SC considered two statements on this topic and was aligned with recommendations from numerous societies worldwide (Figure 3, Statements 39 and 40). First, patients treated with DMF have not shown an increased risk of severe COVID-19 infection.¹⁶⁷ It is recommended that DMT selection should continue to be based on the activity and severity of the MS²⁹ and that the risks from MS outweigh those of COVID-19 in most cases.^{85,168,169} Patients with MS may experience a diminished response to vaccines, depending on the DMT which they are receiving and its mechanism of action.^{29,87,170,171} The patient response to vaccination, including for COVID-19, has been found to be intact during treatment with DMF, and the

AE profiles of the influenza and COVID-19 vaccines have not been shown to be influenced by DMF.^{29,87,172,173} DMF does not interact with vaccines for COVID-19 and patients taking DMF should continue therapy, independent of vaccination timing.^{29,167} Data attained with influenza vaccination suggest that vaccine use does not increase the risk of subclinical disease activity in DMF-treated patients.⁸⁷

Pregnancy/lactation

Overall, the lack of accumulation of DMF/MMF makes it suitable for use in *proximity* to pregnancy, although it should still be discontinued during pregnancy (Figure 3, Statements 41–44).

DMF has shown some developmental toxicity at clinically relevant doses in animal studies but not in human populations.^{174–180} In the United States, DMF is pregnancy category C, meaning it should be discontinued when a patient wants to become pregnant.^{10–12,55,175} In humans, there is no evidence of reduced fertility or increased risk of congenital malformation or miscarriage rates with inadvertent exposure to DMF in pregnant patients within the first trimester.^{174–180} Clinical evidence is limited, meaning that the characteristics of DMF's formulation contribute to its recommended use. Namely, DMF does not accumulate, so no washout period is required before patients who have been treated with DMF wish to attempt pregnancy.¹⁸¹

There are very few published works considering the issue of DMF during breastfeeding. Any potential use of DMF during breastfeeding will need to balance the benefits and potential risks.^{10–12,182} The primary active metabolite of DMF (MMF) has been detected in small quantities in breast milk in a small case study of two lactating patients.¹⁸³ The authors concluded the risk to the infant was likely to be low, considering the low concentration levels, but there is too little evidence to be confident in this regard.¹⁸³

Aside from pregnancy and breastfeeding, avoiding pregnancy via contraception may be influenced by DMT choice. Norgestimate/ethinyl estradiol oral contraceptives have been studied in a small RCT in combination with DMF, without impact on the efficacy or tolerability of either class of agent.¹⁶⁶ These study findings accord with the DMF prescribing information, which indicates no drug-drug interactions.^{10–12} A United

Kingdom consensus on MS and pregnancy also advises that DMF does not reduce the effectiveness of hormonal contraception.¹⁷⁹

Situation in China/East Asia. The DMF prescribing information in China notes that there are no adequate data on developmental risk in pregnant women.¹⁰ The evidence above suggests that therapy should not be continued during pregnancy and that discontinuation of DMF can occur close to pregnancy confirmation and does not need to be stopped (washed out) for a long period in advance of attempts to become pregnant.¹⁸¹ For breastfeeding, the Chinese label agrees that the risks and benefits of treatment on the mother and the breastfed infant should be considered when making treatment decisions. Family planning and fertility are very important considerations for female MS patients in China, but no differences in practice with DMF are likely based on the generated data.

Paediatrics

DMF has only limited data in paediatric populations, with trial data generated only from the FOCUS and CONNECTED studies of ~20 paediatric patients. In these trials, DMF performed similarly as in adult populations in terms of both efficacy and tolerability (Figure 3, Statement 45).^{184,185} In the FOCUS trial, AEs that were common with DMF in paediatric patients included headache ($n=4$, 18%), dysmenorrhea ($n=2$, 9%), GI disorders ($n=12$, 55%) and respiratory, thoracic and mediastinal symptoms such as cough ($n=3$, 14%) and upper respiratory tract infection ($n=2$, 9%).¹⁸⁴ Data from a limited number of case reports, cohort studies and retrospective observational studies support the similarity of DMF performance in paediatric and adult populations (Figure 3, Statement 45).^{186–189} The CONNECT study, a phase III open-label randomized clinical trial of DMF ($n=78$) against IFN- β 1a ($n=72$), has recently shown that DMF was well tolerated, with favourable MRI and adjusted ARR for DMF-treated paediatric patients;¹⁹⁰ noting it was published after this article's evidence review and it will be considered more completely in future work.

Discussion

More than half a million patients have been treated with DMF since its launch in 2013 (data

on file).²³ The statements agreed in this article were generated by reviewing over a decade of literature on DMF, spanning the original pivotal clinical trials through to the most recent post-marketing data. The data for DMF have remained largely consistent over time.²⁶ In terms of safety, no new signals have emerged since existing reviews. A small number of PML cases have accumulated, but the condition remains very rare (data on file).⁹⁵ The expert opinion of the SC, therefore, supports the positive efficacy and safety profile of DMF as a first-line and switch therapy agent in patients with RRMS and, if permitted by the local label, CIS.

The most recent estimates of MS prevalence in China are 2.39 per 100,000, meaning a potential MS population within the country of more than 34,000.³ This represents a large new population of patients who could potentially be exposed to and/or benefit from DMF.

Despite over a decade of experience with DMF, data from ethnically Chinese populations comprise a small fraction of the existing data,³ which presents challenges for understanding how DMF will be used in practice in this country.⁴⁸ Post-marketing data from within China will be valuable for further understanding the characteristics of DMF in this population. Important differences within China may include the background prevalence of relevant diseases such as hepatitis and tuberculosis,^{89,116} differences in the MS treatment armamentarium available, prevailing practices on patient acceptance of DMTs and healthcare professional attitudes towards MS management and its relative importance as a rare disease.³ Monitoring infrastructure for serial (follow-up) neuroimaging and/or serology for hepatitis and tuberculosis may also be impacted by regional differences in availability and implementation priority.

The possibility of drug interactions with as-yet-unidentified Chinese medicine products cannot be categorically excluded, and the real-world use patterns of DMF along with the Chinese diet and cultural practices regarding traditional medicine will be a source of new data following its increased use in the country. Nonetheless, with the evidence generated to date, it is anticipated that DMF will behave similarly in the Chinese population as with the rest-of-the-world population. This is consistent with the confidence of the Chinese regulatory agencies in approving DMF for use in

MS treatment,¹⁰ based on similar predictions of maintained safety and efficacy in the population.

Obstacles to rational uptake in China will be confusion regarding the monitoring and testing requirements; for example, about whether JCV and latent tuberculosis testing need to be conducted. It should be made clear that neither JCV nor latent tuberculosis testing needs to be performed. Despite this, it is important that clinicians remain vigilant for PML risk alongside any other AEs.

The panel considered additional statements on the role of the gut microbiome in the aetiology of MS and potential influence on DMF efficacy but found insufficient evidence to proceed. This will be a topic of interest in the future as more evidence accumulates.^{191–193} Similarly, data from paediatric populations and in patients who are pursuing pregnancy or who are breastfeeding are also sparse; it is hoped that more data will be generated in these groups.

Thus, the limitations of the study include the sparsity of data in Asian patients as well as the level and quality of evidence in some areas, making it difficult to make conclusive recommendations on those topics. As more patients in China are treated with DMF and more experience is gathered, a repeated analysis and update of the information presented here should be conducted.

This project revealed a consistency of data suggesting DMF remains a valuable part of the MS treatment armamentarium. This evidence summary hopes to clarify all relevant aspects for more effective use in China.

Conclusion

A decade of experience with DMF continues to support its positive efficacy and safety profile in treating patients with MS. Although there is a paucity of high-quality evidence from China itself, the limited data that exist from East Asian populations support a similar profile and suggest that DMF will be a valuable addition to the MS therapeutic armamentarium and will help address unmet treatment needs in China. This review of the most recent and extensive previous literature to form conclusive summary statements is aimed to provide a relevant overview to all clinicians treating patients with MS, with the aims of optimizing care and patient outcomes.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Author contributions

Ralf Gold: Conceptualization; Formal analysis; Supervision; Writing – review & editing.

Michael Barnett: Conceptualization; Formal analysis; Writing – review & editing.

Andrew Chan: Conceptualization; Formal analysis; Writing – review & editing.

Huiyu Feng: Conceptualization; Formal analysis; Writing – review & editing.

Kazuo Fujihara: Conceptualization; Formal analysis; Writing – review & editing.

Gavin Giovannoni: Conceptualization; Formal analysis; Writing – review & editing.

Xavier Montalbán: Conceptualization; Formal analysis; Writing – review & editing.

Fu-Dong Shi: Conceptualization; Formal analysis; Writing – review & editing.

Mar Tintoré: Conceptualization; Formal analysis; Writing – review & editing.

Qun Xue: Conceptualization; Formal analysis; Writing – review & editing.

Chunsheng Yang: Conceptualization; Formal analysis; Writing – review & editing.

Hongyu Zhou: Conceptualization; Formal analysis; Writing – review & editing.

Acknowledgements

The Steering Committee authors acknowledge and thank all experts who contributed to the voting and discussion, refining the draft statements. Jeffrey Martin and Rachael Profit (MIMS, Hong Kong and Pte Limited) contributed to the literature search, project administration, visualization of the voting data and medical writing assistance to the manuscript preparation.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This Steering Committee initiative was sponsored by Biogen.

Writing and editorial assistance was funded by Biogen and provided by MIMS (Hong Kong and Pte) Limited.

Competing interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Ralf Gold has received research support and speaker's honoraria from Bayer Schering, Biogen, Bristol Myers Squibb, Chugai, Eisai, Janssen, Merck Serono, Nikkiso Pharma, Novartis, Roche, Sanofi Genzyme and TEVA; and consulting honoraria from ZLB Behring, Baxter, Merck, MIMS and Talecris. He holds personal stock options in Bayer, Merck, Novartis and Roche. Dr Michael Barnett has received institutional support for research or speaking from Alexion, Biogen, Merck, Roche, BMS and Sanofi Genzyme; is Research Director, Sydney Neuroimaging Analysis Centre and Research Consultant, RxMx. Dr Andrew Chan has received speakers'/board honoraria from Actelion (Janssen/Johnson & Johnson), Alexion, Almirall, Bayer, Biogen, Bristol Myers Squibb (Celgene), Genzyme, Merck KGaA (Darmstadt, Germany), Novartis, Roche and Teva, all for hospital research funds. Beyond this project, Dr Huiyu Feng has no further disclosures. Dr Kazuo Fujihara serves as an advisor or on scientific advisory boards for Biogen, Mitsubishi Tanabe, Novartis, Chugai/Roche, Alexion, VielaBio/Horizon Therapeutics, UCB, Merck Biopharma, Japan Tobacco and AbbVie; has received funding for travel and speaker honoraria from Biogen, Eisai, Mitsubishi Tanabe, Novartis, Chugai, Roche, Alexion, VielaBio, Teijin, Asahi Kasei Medical, Merck and Takeda and has received the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labour of Japan. In the last 2 years, Dr Gavin Giovannoni has received compensation for serving as a consultant or speaker for or has received research support from AbbVie, Aslan, Atara Bio, Biogen, Bristol Myers Squibb (Celgene), GlaxoSmithKline, Janssen/J&J, Japan Tobacco, Jazz Pharmaceuticals, LifNano, Merck & Co, Merck KGaA/EMD Serono, Moderna, Novartis, Sanofi and Roche/Genentech. In the last 5 years, Dr Giovannoni has received grant support for research from Biogen, Merck KGaA/EMD Serono, Novartis, Sanofi, Roche/Genentech and

Takeda. Dr Xavier Montalbán has received speaking honoraria and travel expenses for participation in scientific meetings, has been a Steering Committee member of clinical trials or participated in advisory boards of clinical trials in the past years with AbbVie, Actelion, Alexion, Biogen, Bristol Myers Squibb (Celgene), EMD Serono, Genzyme, Hoffmann-La Roche, Immunic Therapeutics, Janssen, MedDay, Merck, Mylan, Nervgen, Novartis, Sandoz, Sanofi Genzyme, Teva Pharmaceuticals, TG Therapeutics, Excemed, Multiple Sclerosis International Federation and National Multiple Sclerosis Society. Beyond this project, Dr Fu-Dong Shi has no further disclosures. Dr Mar Tintoré has received compensation for consulting services, speaking honoraria and research support from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Janssen, Merck Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio and Teva Pharmaceuticals and participates on the Data Safety Monitoring Boards for Parexel and UCB Biopharma. Beyond this project, Dr Qun Xue has no further disclosures. Beyond this project, Dr Chunsheng Yang has no further disclosures. Beyond this project, Dr Hongyu Zhou has no further disclosures.

Availability of data and materials

Not applicable.

ORCID iD

Gavin Giovannoni  <https://orcid.org/0000-0001-9995-1700>

Supplemental material

Supplemental material for this article is available online.

References

- Chan KH, Tsang KL, Ho PW *et al.* Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese. *Clin Neurol Neurosurg* 2011; 113: 617–622.
- Fox RJ, Gold R, Phillips JT *et al.* Efficacy and tolerability of delayed-release dimethyl fumarate in black, Hispanic, and Asian patients with relapsing-remitting multiple sclerosis: post hoc integrated analysis of DEFINE and CONFIRM. *Neurol Ther* 2017; 6: 175–187.
- Jia D, Zhang Y and Yang C. The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: a narrative review. *Neurol Sci* 2022; 43: 4695–4700.
- Zhou R, Zeng Q, Yang H, *et al.* Status of immunotherapy acceptance in Chinese patients with multiple sclerosis: analysis of multiple sclerosis patient survival report 2018. *Front Neurol* 2021; 12: 651511.
- Cheng Q, Miao L, Zhang J, *et al.* A population-based survey of multiple sclerosis in Shanghai, China. *Neurology* 2007; 68: 1495–1500.
- GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2019; 18: 269–285.
- Howard J, Trevick S and Younger DS. Epidemiology of multiple sclerosis. *Neurol Clin* 2016; 34: 919–939.
- Rosati G. The prevalence of multiple sclerosis in the world: an update. *Neurol Sci* 2001; 22: 117–139.
- Walton C, King R, Rechtman L, *et al.* Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. *Mult Scler* 2020; 26: 1816–1821.
- Biogen-Idec. TECFIDERA® prescribing information (China), https://www.biogen.cn/content/dam/corporate/cn_CN/pdf/%E5%AF%8C%E9%A9%AC%E9%85%B8%E4%BA%8C%E7%94%B2%E9%85%AF%E8%82%A0%E6%BA%B6%E8%83%B6%E5%9B%8A%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf (2022, accessed 30 October 2022).
- Biogen-Idec. TECFIDERA® summary of product characteristics (EMA), https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_en.pdf (2022, accessed 30 October 2022).
- Biogen-Idec. TECFIDERA® prescribing information (United States), https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204063s027lbl.pdf (2022, accessed 21 November 2022).
- Linker RA, Lee DH, Ryan S, *et al.* Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain* 2011; 134: 678–692.
- Cada DJ, Levien TL and Baker DE. Dimethyl fumarate. *Hospital Pharmacy* 2013; 48: 668–679.
- Temple R. NDA approval, https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2013/204063Orig1s000ltr.pdf (2013, accessed 31 October 2022).

16. Niino M, Ohashi T, Ochi H, *et al.* Japanese guidelines for dimethyl fumarate. *Clin Exp Neuroimmunol* 2018; 9: 235–243.
17. Lee JH. Pricing and reimbursement pathways of new orphan drugs in South Korea: a longitudinal comparison. *Healthcare* 2021; 9: 296.
18. Biogen Idec gets DCGI nod for multiple sclerosis oral drug, 2015, <https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biogen-idec-gets-dcgi-nod-for-multiple-sclerosis-oral-drug/articleshow/46215644.cms?from=mdr> (2015, accessed 30 October 2022).
19. MIMS. Local product insert, [https://www.mims.com/thailand/drug/tecfidera/local-product-insert/TH%20Package%20leaflet_TECFIDERA_Thai%20PIL_rev3Mar2020-clean_\(rev16Mar20\).pdf](https://www.mims.com/thailand/drug/tecfidera/local-product-insert/TH%20Package%20leaflet_TECFIDERA_Thai%20PIL_rev3Mar2020-clean_(rev16Mar20).pdf) (2020, accessed 31 October 2022).
20. HKDoH. Compendium of pharmaceutical products, <https://www.drugoffice.gov.hk/eps/do/tc/doc/Compdium.pdf> (2020, accessed 1 November 2022).
21. HSA. New drug approvals Singapore July 2016, <https://www.hsa.gov.sg/announcements/new-drug-approval/new-drug-approvals-jul-2016> (2016, accessed 1 November 2022).
22. San-Juan-Rodriguez A, Good CB, Heyman RA, *et al.* Trends in prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis in Medicare part D. *JAMA Neurol* 2019; 76: 1386–1390.
23. Lyons J, Hughes R, McCarthy K, *et al.* Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate. *Mult Scler J Exp Transl Clin* 2022; 8: 20552173221132469.
24. Fox RJ, Kita M, Cohan SL, *et al.* BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. *Curr Med Res Opin* 2014; 30: 251–262.
25. Gold R, Kappos L, Arnold DL, *et al.* Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med* 2012; 367: 1098–1107.
26. Gold R, Arnold DL, Bar-Or A, *et al.* Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. *Mult Scler* 2022; 28: 801–816.
27. Fox RJ, Miller DH, Phillips JT, *et al.* Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. *N Engl J Med* 2012; 367: 1087–1097.
28. Gold R, Arnold DL, Bar-Or A, *et al.* Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. *Mult Scler* 2017; 23: 253–265.
29. Wiendl H, Gold R, Berger T, *et al.* Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). *Ther Adv Neurol Disord* 2021; 14: 17562864211039648.
30. Boulas P. Compounded formulations of dimethyl fumarate show significant variability in product characteristics. *Drug Res* 2016; 66: 275–278.
31. Longbrake EE, Cantoni C, Chahin S, *et al.* Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. *Mult Scler* 2018; 24: 728–738.
32. Liebmann M, Korn L, Janoschka C, *et al.* Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. *Brain* 2021; 144: 3126–3141.
33. Holm Hansen R, Højsgaard Chow H, Sellebjerg F, *et al.* Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis. *Mult Scler* 2019; 25: 1289–1297.
34. Holm Hansen R, Højsgaard Chow H, Christensen JR, *et al.* Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis. *Mult Scler Relat Disord* 2020; 37: 101451.
35. Breuer J, Herich S, Schneider-Hohendorf T, *et al.* Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. *Mult Scler* 2018; 24: 1871–1882.
36. Mansilla MJ, Navarro-Barriuso J, Presas-Rodríguez S, *et al.* Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment. *CNS Neurosci Ther* 2019; 25: 995–1005.
37. McGuire VA, Ruiz-Zorrilla Diez T, Emmerich CH, *et al.* Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation. *Sci Rep* 2016; 6: 31159.
38. Brennan MS, Matos MF, Richter KE, *et al.* The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes. *Sci Rep* 2017; 7: 42054.

39. Edwards KR, Kamath A, Button J, *et al.* A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers. *Mult Scler Relat Disord* 2021; 51: 102861.
40. Gopal S, Mikulskis A, Gold R, *et al.* Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the phase 3 DEFINE and CONFIRM studies. *Mult Scler* 2017; 23: 1875–1883.
41. Suneetha A and Raja Rajeswari K. Role of dimethyl fumarate in oxidative stress of multiple sclerosis: a review. *J Chromatogr B Analyt Technol Biomed Life Sci* 2016; 1019: 15–20.
42. Wipke BT, Hoepner R, Strassburger-Krogias K, *et al.* Different fumaric acid esters elicit distinct pharmacologic responses. *Neurol Neuroimmunol Neuroinflamm* 2021; 8: e950.
43. Yadav SK, Ito N, Soin D, *et al.* Dimethyl fumarate suppresses demyelination and axonal loss through reduction in pro-inflammatory macrophage-induced reactive astrocytes and complement C3 deposition. *J Clin Med* 2021; 10: 857.
44. Longbrake EE, Mao-Draayer Y, Cascione M, *et al.* Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. *Mult Scler* 2021; 27: 883–894.
45. Narapureddy B and Dubey D. Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence. *Patient Prefer Adherence* 2019; 13: 1655–1666.
46. Phillips JT, Hutchinson M, Fox R, *et al.* Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. *Mult Scler Relat Disord* 2014; 3: 513–519.
47. Fox EJ, Vasquez A, Grainger W, *et al.* Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). *Int J MS Care* 2016; 18: 9–18.
48. Saida T, Yamamura T, Kondo T, *et al.* A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. *BMC Neurol* 2019; 19: 5.
49. Kondo T, Kawachi I, Onizuka Y, *et al.* Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension. *Mult Scler J Exp Transl Clin* 2019; 5: 2055217319864974.
50. Ochi H, Niino M, Onizuka Y, *et al.* 72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension. *Adv Ther* 2018; 35: 1598–1611.
51. Xu Z, Zhang F, Sun F, *et al.* Dimethyl fumarate for multiple sclerosis. *Cochrane Database Syst Rev* 2015; 22: CD011076.
52. Salter A, Lancia S, Cutter G, *et al.* A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod. *Ther Adv Neurol Disord* 2021; 14: 17562864211021177.
53. Li H, Hu F, Zhang Y, *et al.* Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. *J Neurol* 2020; 267: 3489–3498.
54. Freedman MS, Devonshire V, Duquette P, *et al.* Treatment optimization in multiple sclerosis: Canadian MS working group recommendations. *Can J Neurol Sci* 2020; 47: 437–455.
55. Montalban X, Gold R, Thompson AJ, *et al.*ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. *Mult Scler* 2018; 24: 96–120.
56. Rae-Grant A, Day GS, Marrie RA, *et al.* Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. *Neurology* 2018; 90: 777–788.
57. Salter A, Lancia S, Cutter G, *et al.* Characterizing long-term disability progression and employment in NARCOMS registry participants with multiple sclerosis taking dimethyl fumarate. *Int J MS Care* 2021; 23: 239–244.
58. Gold R, Giovannoni G, Phillips JT, *et al.* Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. *Neurol Ther* 2016; 5: 45–57.

59. Cerqueira JJ, Compston DAS, Gerales R, *et al.* Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? *J Neurol Neurosurg Psychiatry* 2018; 89: 844–850.
60. Hänninen K, Viitala M, Atula S, *et al.* Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study. *J Neurol* 2022; 269: 913–922.
61. Walo-Delgado PE, De la Maza SS, Villarrubia N, *et al.* Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment. *Sci Rep* 2021; 11: 9299.
62. Delcoigne B, Manouchehrinia A, Barro C, *et al.* Blood neurofilament light levels segregate treatment effects in multiple sclerosis. *Neurology* 2020; 94: e1201–e1212.
63. Sejbaek T, Nielsen HH, Penner N, *et al.* Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients. *J Neurol Neurosurg Psychiatry* 2019; 90: 1324–1330.
64. West T, Wyatt M, High A, *et al.* Are initial demyelinating event recovery and time to second event under differential control? *Neurology* 2006; 67: 809–813.
65. Fox RJ, Chan A, Gold R, *et al.* Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. *Neurol Clin Pract* 2016; 6: 220–229.
66. Goldman MD, Dwyer L, Coleman R, *et al.* Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients. *PLoS ONE* 2020; 15: e0228617.
67. Mehta D, Miller C, Arnold DL, *et al.* Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice. *Neurology* 2019; 92: e1724–e1738.
68. Warny M, Helby J, Nordestgaard BG, *et al.* Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. *PLoS Med* 2018; 15: e1002685.
69. Kim T, Croteau D, Brinker A, *et al.* Expanding spectrum of opportunistic infections associated with dimethyl fumarate. *Mult Scler* 2021; 27: 1301–1305.
70. Garbo R, Lorenzut S, Del Negro I, *et al.* Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment. *Mult Scler Relat Disord* 2021; 49: 102781.
71. Tsantes E, Curti E, Ferraro D, *et al.* Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis. *Eur J Neurol* 2021; 28: 269–277.
72. Boffa G, Bruschi N, Cellerino M, *et al.* Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population. *CNS Drugs* 2020; 34: 425–432.
73. Perini P, Rinaldi F, Puthenparampil M, *et al.* Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient. *Mult Scler Relat Disord* 2018; 26: 68–70.
74. Greenstein JI. Diffuse dermatophytosis occurring on dimethyl fumarate therapy. *Mult Scler* 2018; 24: 999–1001.
75. Workel HH, Wolfhagen MJHM, Bouwhuis JW, *et al.* Cryptococcal meningitis in a patient with multiple sclerosis on dimethyl fumarate treatment: a case report. *Mult Scler Relat Disord* 2020; 42: 102137.
76. Scotto R, Reia A, Buonomo AR, *et al.* Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. *Expert Opin Drug Saf* 2021; 20: 925–936.
77. Kogel AK, Gold R and Schneider R. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient. *J Neurol* 2021; 268: 4374–4375.
78. Rastas C, Sirignano D, Barner A, *et al.* Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis. *J Neurol* 2019; 266: 2867–2868.
79. Loreface L, Fenu G, Cabras F, *et al.* An unusual infection in MS patient treated with dimethyl fumarate: a case report of omphalitis. *Mult Scler Relat Disord* 2016; 7: 65–67.
80. Berkovich R and Weiner LP. Effects of dimethyl fumarate on lymphocyte subsets. *Mult Scler Relat Disord* 2015; 4: 339–341.
81. Manni A, Iaffaldano A, Lucisano G, *et al.* Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort. *Front Immunol* 2019; 10: 1343.
82. Medina S, Villarrubia N, Sainz de la Maza S, *et al.* Optimal response to dimethyl

- fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. *Mult Scler* 2018; 24: 1317–1327.
83. Chan A, Rose J, Alvarez E, *et al.* Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. *Neurol Clin Pract* 2020; 10: 510–519.
 84. Monschein T, Hartung HP, Zrzavy T, *et al.* Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. *J Neurol Neurosurg Psychiatry* 2021; 92: 1033–1043.
 85. Szepanowski F, Warnke C, Zu Hörste MG, *et al.* Secondary immunodeficiency and risk of infection following immune therapies in neurology. *CNS Drugs* 2021; 35: 1173–1188.
 86. Von Hehn C, Howard J, Liu S, *et al.* Immune response to vaccines is maintained in patients treated with dimethyl fumarate. *Neurol Neuroimmunol Neuroinflamm* 2018; 5: e409.
 87. Moser T, Seiberl M, Feige J, *et al.* Tetravalent influenza vaccine is not associated with neuroaxonal damage in multiple sclerosis patients. *Front Immunol* 2021; 12: 718895.
 88. European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2021–2019 data, <https://www.ecdc.europa.eu/en/publications-data/tuberculosis-surveillance-and-monitoring-europe-2021-2019-data> (2021, accessed 9 October 2022).
 89. Yu S, Ma J and Jia Z. Estimating the incidence of tuberculosis – Shanghai, China, 2025–2050. *China CDC Wkly* 2020; 2: 995–998.
 90. Baldassari LE, Feng J, Macaron G, *et al.* Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting. *Mult Scler J Exp Transl Clin* 2019; 5: 2055217319875467.
 91. Dantas LA, Pereira MS, Gauza AM, *et al.* Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: a systematic review. *Mult Scler Relat Disord* 2021; 55: 103184.
 92. Epstein DJ, Dunn J and Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. *Open Forum Infect Dis* 2018; 5: ofy174.
 93. Fragoso YD, Adoni T, Anacleto A, *et al.* How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis? *Expert Rev Neurother* 2014; 14: 1251–1260.
 94. Getahun H, Matteelli A, Chaisson RE, *et al.* Latent mycobacterium tuberculosis infection. *N Engl J Med* 2015; 372: 2127–2135.
 95. Jordan AL, Yang J, Fisher CJ, *et al.* Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. *Mult Scler* 2022; 28: 7–15.
 96. Berger JR. Classifying PML risk with disease modifying therapies. *Mult Scler Relat Disord* 2017; 12: 59–63.
 97. Diebold M, Altersberger V, Décard BF, *et al.* A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. *Mult Scler* 2019; 25: 1682–1685.
 98. Lucchini M, Prosperini L, Buscarinu MC, *et al.* Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. *J Neurol* 2021; 268: 2238–2245.
 99. Caldito NG, O’Leary S and Stuve O. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation. *Mult Scler* 2021; 27: 1306–1308.
 100. Wood CH, Robertson NP, Htet ZM, *et al.* Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. *Mult Scler Relat Disord* 2022; 58: 103492.
 101. Gieselbach R-J, Muller-Hansma AH, Wijburg MT, *et al.* Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. *J Neurol* 2017; 264: 1155–1164.
 102. Motte J, Kneiphof J, Straßburger-Krogias K, *et al.* Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML. *J Neurol* 2018; 265: 1880–1882.
 103. Vola EA, Petracca M, Cocozza S, *et al.* Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions. *BMC Neurol* 2021; 21: 146.
 104. Dunham SR, Schmidt R and Clifford DB. Treatment of progressive multifocal leukoencephalopathy using immune restoration. *Neurotherapeutics* 2020; 17: 955–965.
 105. Cheng J, Sun Y-N, Zhang C-Y, *et al.* Incidence and risk factors of tuberculosis among the elderly population in China: a prospective cohort study. *Infect Dis Poverty* 2020; 9: 13.

106. Lau A, Qiu W, Kermode A, *et al.* High prevalence and indexes of anti-John Cunningham virus antibodies in a cohort of Chinese patients with multiple sclerosis. *Mult Scler J Exp Transl Clin* 2018; 4: 2055217318788699.
107. Fanara S, Aprile M, Iacono S, *et al.* The role of nutritional lifestyle and physical activity in multiple sclerosis pathogenesis and management: a narrative review. *Nutrients* 2021; 13: 3774.
108. Rapp D, Michels S, Schöpe J, *et al.* Associations between multiple sclerosis and incidence of heart diseases: systematic review and meta-analysis of observational studies. *Mult Scler Relat Disord* 2021; 56: 103279.
109. Kingwell E, Zhang T, Zhu F, *et al.* Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study. *Expert Opin Drug Saf* 2021; 20: 481–487.
110. Guarnera C, Bramanti P and Mazzon E. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. *Drug Des Devel Ther* 2017; 11: 2193–2207.
111. Antonazzo IC, Poluzzi E, Forcesi E, *et al.* Liver injury with drugs used for multiple sclerosis: a contemporary analysis of the FDA adverse event reporting system. *Mult Scler* 2019; 25: 1633–1640.
112. Biolato M, Bianco A, Lucchini M, *et al.* The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review. *CNS Drugs* 2021; 35: 861–880.
113. Gold R, Giovannoni G, Phillips JT, *et al.* Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). *Mult Scler* 2015; 21: 57–66.
114. Diebold M, Fischer-Barnicol B, Tsagkas C, *et al.* Hepatitis E virus infections in patients with MS on oral disease-modifying treatment. *Neurol Neuroimmunol Neuroinflamm* 2019; 6: e594.
115. Muñoz MA, Kulick CG, Kortepeter CM, *et al.* Liver injury associated with dimethyl fumarate in multiple sclerosis patients. *Mult Scler* 2017; 23: 1947–1949.
116. Yue T, Zhang Q, Cai T, *et al.* Trends in the disease burden of HBV and HCV infection in China from 1990–2019. *Int J Infect Dis* 2022; 122: 476–485.
117. Lebrun C and Rocher F. Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs. *CNS Drugs* 2018; 32: 939–949.
118. Gómez-Moreno M, Sánchez-Seco VG, Moreno-García S, *et al.* Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment. *Mult Scler Relat Disord* 2021; 49: 102747.
119. Gil-Bernal R, González-Caballero JL, Espinosa-Rosso R, *et al.* Potential risk of disease modifying therapies on neoplasm development and coadjuvant factors in multiple sclerosis outpatients. *Sci Rep* 2021; 11: 12533.
120. Stamatellos VP, Siafis S and Papazisis G. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: a disproportionality analysis using the US Food and Drug Administration adverse event reporting system database. *Br J Clin Pharmacol* 2021; 87: 4769–4779.
121. Dolladille C, Chrétien B, Peyro-Saint-Paul L, *et al.* Association between disease-modifying therapies prescribed to persons with multiple sclerosis and cancer: a WHO pharmacovigilance database analysis. *Neurotherapeutics* 2021; 18: 1657–1664.
122. Repovic P, Robertson D, Kresa-Reahl K, *et al.* Effectiveness of dimethyl fumarate in patients with relapsing multiple sclerosis switching after suboptimal response to glatiramer acetate, including patients with early multiple sclerosis: subgroup analysis of RESPOND. *Neurol Ther* 2021; 10: 169–182.
123. Deleu D, Mesraoua B, Canibano B, *et al.* Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview. *Curr Med Res Opin* 2019; 35: 249–260.
124. Chan A, Cutter G, Fox RJ, *et al.* Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. *J Comp Eff Res* 2017; 6: 313–323.
125. Paolicelli D, Manni A, Iaffaldano A, *et al.* Efficacy and safety of oral therapies for relapsing-remitting multiple sclerosis. *CNS Drugs* 2020; 34: 65–92.
126. D’Amico E, Zanghi A, Sciandra M, *et al.* Dimethyl fumarate vs teriflunomide: an Italian time-to-event data analysis. *J Neurol* 2020; 267: 3008–3020.
127. Condé S, Moisset X, Pereira B, *et al.* Dimethyl fumarate and teriflunomide for multiple

- sclerosis in a real-life setting: a French retrospective cohort study. *Eur J Neurol* 2019; 26: 460–467.
128. Braune S, Grimm S, Van Hövell P, *et al.* Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. *J Neurol* 2018; 265: 2980–2992.
 129. Laplaud DA, Casey R, Barbin L, *et al.* Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. *Neurology* 2019; 93: e635–e646.
 130. Buron MD, Chalmer TA, Sellebjerg F, *et al.* Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. *Neurology* 2019; 92: e1811–e1820.
 131. Buron MD, Kalincik T, Sellebjerg F, *et al.* Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. *J Neurol Neurosurg Psychiatry* 2021; 92: 556–562.
 132. Granqvist M, Burman J, Gunnarsson M, *et al.* Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. *Mult Scler* 2020; 26: 1532–1539.
 133. Sabin J, Urriaga S, Pilo B, *et al.* Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. *J Neurol* 2020; 267: 2362–2371.
 134. Wicks P, Rasouliyan L, Katic B, *et al.* The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. *BMC Res Notes* 2016; 9: 434.
 135. Campbell TL, Lefaux BJ, Mayer LL, *et al.* Nursing management of gastrointestinal adverse events associated with delayed-release dimethyl fumarate: a global Delphi approach. *J Neurosci Nurs* 2020; 52: 72–77.
 136. Mayer L, Fink MK, Sammarco C, *et al.* Management strategies to facilitate optimal outcomes for patients treated with delayed-release dimethyl fumarate. *Drug Saf* 2018; 41: 347–356.
 137. Sejbaek T, Nybo M, Petersen T, *et al.* Real-life persistence and tolerability with dimethyl fumarate. *Mult Scler Relat Disord* 2018; 24: 42–46.
 138. Lenzen SA, Daniëls R, van Bokhoven MA, *et al.* Setting goals in chronic care: shared decision making as self-management support by the family physician. *Eur J Gen Pract* 2015; 21: 138–144.
 139. Askari S, Pappas C, De Smit C, *et al.* Comparison of goals set by people with multiple sclerosis during two fatigue management interventions. *Scand J Occup Ther* 2022; 30: 684–692.
 140. Carrithers MD. Update on disease-modifying treatments for multiple sclerosis. *Clin Ther* 2014; 36: 1938–1945.
 141. Ben-Zacharia A, Adamson M, Boyd A, *et al.* Impact of shared decision making on disease-modifying drug adherence in multiple sclerosis. *Int J MS Care* 2018; 20: 287–297.
 142. Rodrigues R, Rocha R, Bonifácio G, *et al.* Therapeutic inertia in relapsing-remitting multiple sclerosis. *Mult Scler Relat Disord* 2021; 55: 103176.
 143. Fox EJ and Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. *Curr Opin Neurol* 2012; 25(Suppl.): S11–9.
 144. Pandit L. No evidence of disease activity (NEDA) in multiple sclerosis – shifting the goal posts. *Ann Indian Acad Neurol* 2019; 22: 261–263.
 145. Giovannoni G, Gold R, Fox RJ, *et al.* Relapses requiring intravenous steroid use and multiple-sclerosis-related hospitalizations: integrated analysis of the delayed-release dimethyl fumarate phase III studies. *Clin Ther* 2015; 37: 2543–2551.
 146. Barros A, Sequeira J, de Sousa A, *et al.* Real-world effectiveness and safety of dimethyl fumarate in a multiple sclerosis Portuguese population. *Clin Neuropharmacol* 2020; 43: 55–60.
 147. Ontaneda D, Nicholas J, Carraro M, *et al.* Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. *Mult Scler Relat Disord* 2019; 27: 101–111.
 148. Miclea A, Leussink VI, Hartung HP, *et al.* Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. *J Neurol* 2016; 263: 1626–1632.
 149. Lanzillo R, Moccia M, Palladino R, *et al.* Clinical predictors of dimethyl fumarate response in multiple sclerosis: a real life multicentre study. *Mult Scler Relat Disord* 2020; 38: 101871.
 150. Pilo de la Fuente B, Sabin J, Galán V, *et al.* Three-year effectiveness of dimethyl fumarate in multiple sclerosis: a prospective multicenter

- real-world study. *CNS Drugs* 2020; 34: 1275–1286.
151. Loreface L, Casaglia E, Fronza M, *et al.* The dimethyl fumarate experience: a handy drug with broad clinical utility. *Front Neurol* 2021; 12: 679355.
 152. Phillips JT, Selmaj K, Gold R, *et al.* Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. *Int J MS Care* 2015; 17: 236–243.
 153. Lorscheider J, Benkert P, Lienert C, *et al.* Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis. *J Neurol* 2021; 268: 941–949.
 154. Eriksson I, Cars T, Piehl F, *et al.* Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. *Eur J Clin Pharmacol* 2018; 74: 219–226.
 155. Khatri BO, Tarima SS, Essig B, *et al.* Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies. *Mult Scler Relat Disord* 2017; 18: 60–64.
 156. Lahdenperä S, Soilu-Hänninen M, Kuusisto HM, *et al.* Medication adherence/persistence among patients with active multiple sclerosis in Finland. *Acta Neurol Scand* 2020; 142: 605–612.
 157. Min J, Cohan S, Alvarez E, *et al.* Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes. *Neurol Ther* 2019; 8: 109–119.
 158. Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. *Acta Neurol Scand* 2017; 136: 168–186.
 159. O’Gorman J, Russell HK, Li J, *et al.* Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. *Clin Ther* 2015; 37: 1402–1419.e5.
 160. Sheikh SI, Nestorov I, Russell H, *et al.* Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. *Clin Ther* 2013; 35: 1582–1594.
 161. Gelibter S, Orrico M, Moiola L, *et al.* Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis. *J Neurol Sci* 2020; 418: 117104.
 162. Antolin-Amerigo D, Sánchez-González MJ, Barbarroja-Escudero J, *et al.* Delayed hypersensitivity reaction to oral dimethyl fumarate. *J Investig Allergol Clin Immunol* 2018; 28: 201–203.
 163. Algahtani H, Shirah B, Marghalani S, *et al.* Erythema nodosum in a patient with multiple sclerosis on dimethyl fumarate. *Mult Scler Relat Disord* 2019; 28: 155–158.
 164. Boulosa-Lale S, González-Freire L, Martínez-Martínez L, *et al.* Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis. *Farm Hosp* 2020; 45: 73–76.
 165. Di Bona D, Albanesi M, Giliberti LA, *et al.* Desensitization for immediate hypersensitivity to oral dimethyl fumarate (tecfidera). *J Allergy Clin Immunol Pract* 2017; 5: 821–822.
 166. Zhu B, Nestorov I, Zhao G, *et al.* Evaluation of potential drug-drug interaction between delayed-release dimethyl fumarate and a commonly used oral contraceptive (norgestimate/ethinyl estradiol) in healthy women. *Clin Pharmacol Drug Dev* 2017; 6: 604–613.
 167. Mantero V, Abate L, Basilico P, *et al.* COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. *J Neurol* 2021; 268: 2023–2025.
 168. Centonze D, Rocca MA, Gasperini C, *et al.* Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. *J Neurol* 2021; 268: 3961–3968.
 169. Korsukewitz C, Reddel SW, Bar-Or A, *et al.* Neurological immunotherapy in the era of COVID-19 – looking for consensus in the literature. *Nat Rev Neurol* 2020; 16: 493–505.
 170. Reder AT, Centonze D, Naylor ML, *et al.* COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. *CNS Drugs* 2021; 35: 317–330.
 171. Sormani MP, De Rossi N, Schiavetti I, *et al.* Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. *Ann Neurol* 2021; 89: 780–789.
 172. Inshasi J, Alroughani R, Al-Asmi A, *et al.* Expert consensus and narrative review on the management of multiple sclerosis in the Arabian Gulf in the COVID-19 era: focus on disease-modifying therapies and vaccination against COVID-19. *Neurol Ther* 2021; 10: 539–555.
 173. Achiron A, Mandel M, Dreyer-Alster S, *et al.* Humoral immune response in multiple sclerosis

- patients following PfizerBNT162b2 COVID19 vaccination: up to 6 months cross-sectional study. *J Neuroimmunol* 2021; 361: 577746.
174. Gold R, Phillips JT, Havrdova E, *et al.* Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. *Neurol Ther* 2015; 4: 93–104.
 175. Biotti D and Ciron J. First-line therapy in relapsing remitting multiple sclerosis. *Rev Neurol* 2018; 174: 419–428.
 176. Amato MP and Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. *CNS Drugs* 2015; 29: 207–220.
 177. Yeh WZ, Widyastuti PA, Van der Walt A, *et al.* Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. *Neurology* 2021; 96: e2989–e3002.
 178. Hellwig K, Rog D, McGuigan C, *et al.* Interim analysis of pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. *Neurol Neuroimmunol Neuroinflamm* 2022; 9: e1114.
 179. Dobson R, Dassan P, Roberts M, *et al.* UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. *Pract Neurol* 2019; 19: 106–114.
 180. Varytė G, Zakarevičienė J, Ramašauskaitė D, *et al.* Pregnancy and multiple sclerosis: an update on the disease modifying treatment strategy and a review of pregnancy’s impact on disease activity. *Medicina* 2020; 56: 49.
 181. Lu E, Wang BW, Alwan S, *et al.* A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. *CNS Drugs* 2014; 28: 89–94.
 182. Capone F, Albanese A, Quadri G, *et al.* Disease-modifying drugs and breastfeeding in multiple sclerosis: a narrative literature review. *Front Neurol* 2022; 13: 851413.
 183. Ciplea AI, Datta P, Rewers-Felkins K, *et al.* Dimethyl fumarate transfer into human milk. *Ther Adv Neurol Disord* 2020; 13: 1756286420968414.
 184. Alroughani R, Das R, Penner N, *et al.* Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS). *Pediatr Neurol* 2018; 83: 19–24.
 185. Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M, *et al.* Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis. *Front Neurol* 2020; 11: 606418.
 186. Krysko KM, Graves J, Rensel M, *et al.* Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. *Neurology* 2018; 91: e1778–e1787.
 187. Krysko KM, Graves JS, Rensel M, *et al.* Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. *Ann Neurol* 2020; 88: 42–55.
 188. Makhani N and Schreiner T. Oral dimethyl fumarate in children with multiple sclerosis: a dual-center study. *Pediatr Neurol* 2016; 57: 101–104.
 189. Saijo N, Abe Y, Oikawa Y, *et al.* Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis. *Brain Dev* 2022; 44: 353–356.
 190. Vermersch P, Scaramozza M, Levin S, *et al.* Effect of dimethyl fumarate vs interferon β -1a in patients with pediatric-onset multiple sclerosis. *JAMA Netw Open* 2022; 5: e2230439.
 191. Dello Russo C, Scott KA and Pirmohamed M. Dimethyl fumarate induced lymphopenia in multiple sclerosis: a review of the literature. *Pharmacol Ther* 2021; 219: 107710.
 192. Katz Sand I, Zhu Y, Ntranos A, *et al.* Disease-modifying therapies alter gut microbial composition in MS. *Neurol Neuroimmunol Neuroinflamm* 2019; 6: e517.
 193. Shah S, Locca A, Dorsett Y, *et al.* Alterations of the gut mycobiome in patients with MS. *EBioMedicine* 2021; 71: 103557.